PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

BACKGROUND: Although immune checkpoint inhibitors have revolutionized cancer treatment, clinical benefit with this class of agents has been limited to a subset of patients. Hence, more effective means to target tumor cells that express immune checkpoint molecules should be developed. For the first t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Immunother Cancer
Auteurs principaux: Fabian, Kellsye P, Padget, Michelle R, Donahue, Renee N., Solocinski, Kristen, Robbins, Yvette, Allen, Clint T., Lee, John H., Rabizadeh, Shahrooz, Soon-Shiong, Patrick, Schlom, Jeffrey, Hodge, James W
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2020
Sujets:
Clinical/Translational Cancer Immunotherapy
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7247398/
https://ncbi.nlm.nih.gov/pubmed/32439799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000450
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires